Targets › IMPA1
1 program from 1 company in 9 trials: 3 Phase 1, 3 Phase 4, 2 Phase 2, 1 Phase 3; Neurology, Oncology, Other; next expected readout Dec 2026.
Phosphatase involved in the dephosphorylation of myo-inositol monophosphates to generate myo-inositol. Is also able to dephosphorylate scyllo-inositol-phosphate, myo-inositol 1,4-diphosphate, scyllo-inositol-1,3-diphosphate and scyllo-inositol-1,4-diphosphate. (UniProt, P29218)
Open in Phaseline: the race on IMPA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alzamend Neuro | Lithium Carbonate (AL001) Inositol-1(or 4)-monophosphatase 1 inhibitor; Glycogen synthase kinase-3 inhibitor | IMPA1, GSK3A, GSK3B | Phase 1 | Bipolar I Disorder; Healthy; Bipolar II Disorder; Depression, Bipolar … | Dec 2026 |
Bipolar I Disorder (1) Healthy (1) Bipolar II Disorder (1) Depression, Bipolar (1) Bipolar Depression (1) Cornelia De Lange Syndrome (1) Cognitive Impairment (1) Parkinson Disease (1) Proven Pathogenic or Probably Pathogenic TBR1 Variant (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.